Multiple choices for HIV therapy with integrase strand transfer inhibitors
<p>Abstract</p> <p>Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several phase 3...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-12-01
|
| Series: | Retrovirology |
| Subjects: | |
| Online Access: | http://www.retrovirology.com/content/9/1/110 |
| Summary: | <p>Abstract</p> <p>Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several phase 3 clinical trials. The advent of this new class of antiretroviral (ARV) medications represents a major advance in the management of HIV infection, and each of these three drugs can be expected to continue to be an important component of ARV combination regimens.</p> |
|---|---|
| ISSN: | 1742-4690 |